Study of the correlation between H-ras mutation and primary hepatocellular carcinoma

Oncology Letters

Volumn 4, Issue 4, 2012, Pages 779-782

  Sui, Guode ^a   Ma, Xuexiao ^a   Liu, Shiguo ^a   Niu, Haitao ^a   Dong, Qian ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

H ras; HotStarTaq PCR; Mutation; Primary hepatocellular carcinoma; Sequencing

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER TISSUE; CARCINOGENESIS; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTATION RATE; ONCOGENE H RAS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD;

EID: 84864660039     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.832     Document Type: Article

References (15)

1. Luk JM and Liu AM: Proteomics of hepatocellular carcinoma in Chinese patients. OMICS 15: 261-266, 2011.
2. Yang T, Zhang J, Lu JH, Yang LQ, Yang GS, Wu MC and Yu WF: A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort. J Cancer Res Clin Oncol 137: 739-750, 2011.
3. Davies M, Prime SS, Eveson J W, Price N, Ganapathy A, D'Mello A and Paterson IC: Transforming growth factor-β enhances invasion and metastasis in Ras-transfected human malignant epidermal keratinocytes. Int J Exp Pathol 93: 148-156, 2012.
4. Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L and Chen YH: The anti-inf lammatory TIPE2 is an inhibitor of the oncogenic Ras. Mol Cell 45: 610-618, 2012.
5. Overmeyer JH and Maltese WA: Death pathways triggered by activated Ras in cancer cells. Front Biosci 16: 1693-1713, 2011.
6. Cullen JM, Williams C, Zadrozny L, Otstot JT, Solomon GG, Sills RC and Hong HH: H-ras consensus sequence and mutations in primary hepatocellular carcinomas of lemurs and lorises. Vet Pathol 48: 868-874, 2011.
7. Zhou X D: Recurrence and metastasis of hepatocel lular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int 1: 35-41, 2002.
8. Regina S, Rollin J, Bléchet C, Iochmann S, Reverdiau P and Gruel Y: Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 3: 689-697, 2008.
9. Zuo Q, Huang H, Shi M, Zhang F, Sun J, Bin J, Liao Y and Liao W: Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. Anat Rec (Hoboken) 295: 423-431, 2012.
10. Hoenerhoff MJ, Chu I, Barkan D, Liu ZY, Datta S, Dimri GP and Green JE: BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 28: 3022-3032, 2009.
11. Lo HW: Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. Curr Cancer Drug Targets 10: 840-848, 2010.
12. Buhrman G, O'Connor C, Zerbe B, Kearney BM, Napoleon R, Kovrigina EA, Vajda S, Kozakov D, Kovrigin EL and Mattos C: Analysis of binding site hot spots on the surface of Ras GTPase. J Mol Biol 413: 773-789, 2011.
13. Nakamura M, Kitaura J, Enomoto Y, Lu Y, Nishimura K, Isobe M, Ozaki K, Komeno Y, Nakahara F, Oki T, et al: Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras/Raf signaling: Implications for tumorigenesis. Cancer Sci 103: 26-33, 2012.
14. Lee M: Differential physiological effects of Raf-1 k inase pathways linked to protein kinase C activation depending on the stimulus in v-H-ras-transformed cells. Cancer Res Treat 40: 39-44, 2008.
15. Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y and Fan J: Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol: Mar 27, 2012 (Epub ahead of print).